Ovid Therapeutics (OVID) EBT Margin Growth (3y) (2023 - 2025)

Ovid Therapeutics (OVID) EBT Margin Growth (3y) (2023 - 2025) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 66,981.90 Bn 66,981.62 Bn - -
2 Nanobiotix 1,913.50 Bn 1,913.44 Bn - -
3 Akari Therapeutics 959.56 Bn 959.56 Bn - -
4 BeOne Medicines 472.03 Bn 467.24 Bn 1.35 Bn 9,237.00
5 Vertex Pharmaceuticals 122.09 Bn 114.84 Bn 2.59 Bn 441.00
6 Regeneron Pharmaceuticals 70.01 Bn 61.26 Bn 3.31 Bn -408.00
7 Belite Bio 62.34 Bn 62.34 Bn - -
8 Argenx Se 55.99 Bn 50.80 Bn 1.41 Bn 363.00
9 Alnylam Pharmaceuticals 37.49 Bn 34.48 Bn 959.66 Mn 7,297.00
10 Ovid Therapeutics 120.41 Mn -35.11 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2025 2.62 Mn
Sep 30, 2025 9.86 Mn
Mar 31, 2025 -676,207.00
Mar 31, 2024 -798,605.00
Dec 31, 2023 -1.04 Mn
Sep 30, 2023 -1.01 Mn